VEGFA and head and neck squamous cell carcinoma: In addition, atezolizumab monotherapy (NCT03452137), atezolizumab in combination with radiotherapy (NCT05053737), atezolizumab in combination with VEGF-A-targeting monoclonal antibody bevacizumab (NCT03818061), and atezolizumab presurgery (NCT05110781) are being investigated for HNSCC (Garcia et al., 2020).